 | • レポートコード：MRC2303H015 • 出版社/出版日：360iResearch / 2022年10月11日 • レポート形態：英語、PDF、220ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医療 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の当調査資料によると、2021年に442.43百万ドルであった世界のレプトスピラ症市場規模は2022年に485.22百万ドルとなり、2027年までに年平均9.92％成長して780.71百万ドルまで拡大すると見込まれています。当書は、レプトスピラ症の世界市場を対象とした調査・分析結果をまとめたものであり、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、治療別分析（アンピシリン、アジスロマイシン、セフトリアキソン、ドキシサイクリン、ペニシリン）、診断別分析（血液培養、全血球計算（CBC）、肝酵素、尿検査）、剤形別分析（カプセル、注射剤、錠剤）、流通チャネル別分析（病院薬局、オンライン薬局、小売薬局）、地域別分析（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）、競争状況、企業情報などの内容を掲載しています。なお、当書内の企業情報としては、Abbott Laboratories、AbbVie Inc.、Almirall, S.A.、AstraZeneca Plc、Aurobindo Pharma、Baxter International, Inc.、Bayer AG、Cipla Inc.、Eli Lilly and Company、Fresenius Kabi AG、GlaxoSmithKline plc、Hikma Pharmaceuticals PLC、Johnson & Johnson Services, Inc.などが含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界のレプトスピラ症市場規模：治療別 - アンピシリンの市場規模 - アジスロマイシンの市場規模 - セフトリアキソンの市場規模 - ドキシサイクリンの市場規模 - ペニシリンの市場規模 ・世界のレプトスピラ症市場規模：診断別 - 血液培養の市場規模 - 全血球計算（CBC）の市場規模 - 肝酵素の市場規模 - 尿検査の市場規模 ・世界のレプトスピラ症市場規模：剤形別 - カプセルの市場規模 - 注射剤の市場規模 - 錠剤の市場規模 ・世界のレプトスピラ症市場規模：流通チャネル別 - 病院薬局チャネルの市場規模 - オンライン薬局チャネルの市場規模 - 小売薬局チャネルの市場規模 ・世界のレプトスピラ症市場規模：地域別 - 南北アメリカのレプトスピラ症市場規模 アメリカのレプトスピラ症市場規模 カナダのレプトスピラ症市場規模 ブラジルのレプトスピラ症市場規模 ... - アジア太平洋のレプトスピラ症市場規模 日本のレプトスピラ症市場規模 中国のレプトスピラ症市場規模 インドのレプトスピラ症市場規模 韓国のレプトスピラ症市場規模 台湾のレプトスピラ症市場規模 ... - ヨーロッパ/中東/アフリカのレプトスピラ症市場規模 イギリスのレプトスピラ症市場規模 ドイツのレプトスピラ症市場規模 フランスのレプトスピラ症市場規模 ロシアのレプトスピラ症市場規模 ... - その他地域のレプトスピラ症市場規模 ・競争状況 ・企業情報 |
The Global Leptospirosis Market size was estimated at USD 442.43 million in 2021 and expected to reach USD 485.22 million in 2022, and is projected to grow at a CAGR 9.92% to reach USD 780.71 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Leptospirosis to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Treatment, the market was studied across Ampicillin, Azithromycin, Ceftriaxone, Doxycycline, Penicillin, and Tetracycline.
Based on Diagnosis, the market was studied across Blood Cultures, Complete Blood Count (CBC), Liver Enzymes, and Urinalysis.
Based on Route of Administration, the market was studied across Oral and Parenteral.
Based on Dosage Form, the market was studied across Capsules, Injections, and Tablets.
Based on Distribution Channel, the market was studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Leptospirosis market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Leptospirosis Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Leptospirosis Market, including Abbott Laboratories, AbbVie Inc., Almirall, S.A., AstraZeneca Plc, Aurobindo Pharma, Baxter International, Inc., Bayer AG, Cipla Inc., Eli Lilly and Company, Fresenius Kabi AG, GlaxoSmithKline plc, Hikma Pharmaceuticals PLC, Johnson & Johnson Services, Inc., Lupin Limited, Merck & Co., Inc., Merck KGaA, Novartis AG, Pfizer Inc, Sun Pharmaceutical Industries Ltd., and Tolmar Pharmaceuticals, Inc..
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Leptospirosis Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Leptospirosis Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Leptospirosis Market?
4. What is the competitive strategic window for opportunities in the Global Leptospirosis Market?
5. What are the technology trends and regulatory frameworks in the Global Leptospirosis Market?
6. What is the market share of the leading vendors in the Global Leptospirosis Market?
7. What modes and strategic moves are considered suitable for entering the Global Leptospirosis Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Significant growth in prevalence of animal-related bacterial infections
5.1.1.2. Favorable governmental initiatives and investments for leptospirosis prevention and control
5.1.1.3. Growing consumer awareness toward possible complications and treatments
5.1.2. Restraints
5.1.2.1. High treatment costs
5.1.3. Opportunities
5.1.3.1. Ongoing research and development activities to launch novel drugs and treatments
5.1.3.2. Development of vaccines for leptospirosis prevention
5.1.4. Challenges
5.1.4.1. Limited availability of drugs due to stringent approval procedures
5.2. Cumulative Impact of COVID-19
6. Leptospirosis Market, by Treatment
6.1. Introduction
6.2. Ampicillin
6.3. Azithromycin
6.4. Ceftriaxone
6.5. Doxycycline
6.6. Penicillin
6.7. Tetracycline
7. Leptospirosis Market, by Diagnosis
7.1. Introduction
7.2. Blood Cultures
7.3. Complete Blood Count (CBC)
7.4. Liver Enzymes
7.5. Urinalysis
8. Leptospirosis Market, by Route of Administration
8.1. Introduction
8.2. Oral
8.3. Parenteral
9. Leptospirosis Market, by Dosage Form
9.1. Introduction
9.2. Capsules
9.3. Injections
9.4. Tablets
10. Leptospirosis Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.3. Online Pharmacy
10.4. Retail Pharmacy
11. Americas Leptospirosis Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Leptospirosis Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Leptospirosis Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. FPNV Positioning Matrix
14.1.1. Quadrants
14.1.2. Business Strategy
14.1.3. Product Satisfaction
14.2. Market Ranking Analysis, By Key Player
14.3. Market Share Analysis, By Key Player
14.4. Competitive Scenario
14.4.1. Merger & Acquisition
14.4.2. Agreement, Collaboration, & Partnership
14.4.3. New Product Launch & Enhancement
14.4.4. Investment & Funding
14.4.5. Award, Recognition, & Expansion
15. Company Usability Profiles
15.1. Abbott Laboratories
15.1.1. Business Overview
15.1.2. Key Executives
15.1.3. Product & Services
15.2. AbbVie Inc.
15.2.1. Business Overview
15.2.2. Key Executives
15.2.3. Product & Services
15.3. Almirall, S.A.
15.3.1. Business Overview
15.3.2. Key Executives
15.3.3. Product & Services
15.4. AstraZeneca Plc
15.4.1. Business Overview
15.4.2. Key Executives
15.4.3. Product & Services
15.5. Aurobindo Pharma
15.5.1. Business Overview
15.5.2. Key Executives
15.5.3. Product & Services
15.6. Baxter International, Inc.
15.6.1. Business Overview
15.6.2. Key Executives
15.6.3. Product & Services
15.7. Bayer AG
15.7.1. Business Overview
15.7.2. Key Executives
15.7.3. Product & Services
15.8. Cipla Inc.
15.8.1. Business Overview
15.8.2. Key Executives
15.8.3. Product & Services
15.9. Eli Lilly and Company
15.9.1. Business Overview
15.9.2. Key Executives
15.9.3. Product & Services
15.10. Fresenius Kabi AG
15.10.1. Business Overview
15.10.2. Key Executives
15.10.3. Product & Services
15.11. GlaxoSmithKline plc
15.11.1. Business Overview
15.11.2. Key Executives
15.11.3. Product & Services
15.12. Hikma Pharmaceuticals PLC
15.12.1. Business Overview
15.12.2. Key Executives
15.12.3. Product & Services
15.13. Johnson & Johnson Services, Inc.
15.13.1. Business Overview
15.13.2. Key Executives
15.13.3. Product & Services
15.14. Lupin Limited
15.14.1. Business Overview
15.14.2. Key Executives
15.14.3. Product & Services
15.15. Merck & Co., Inc.
15.15.1. Business Overview
15.15.2. Key Executives
15.15.3. Product & Services
15.16. Merck KGaA
15.16.1. Business Overview
15.16.2. Key Executives
15.16.3. Product & Services
15.17. Novartis AG
15.17.1. Business Overview
15.17.2. Key Executives
15.17.3. Product & Services
15.18. Pfizer Inc
15.18.1. Business Overview
15.18.2. Key Executives
15.18.3. Product & Services
15.19. Sun Pharmaceutical Industries Ltd.
15.19.1. Business Overview
15.19.2. Key Executives
15.19.3. Product & Services
15.20. Tolmar Pharmaceuticals, Inc.
15.20.1. Business Overview
15.20.2. Key Executives
15.20.3. Product & Services
16. Appendix
16.1. Discussion Guide
16.2. License & Pricing